Provenge at heart of SEC Medicare insider trading probe
This article was originally published in Scrip
Executive Summary
Dendreon's autologous cellular immunotherapy Provenge (sipuleucel-T) is at the heart of a probe by the Securities and Exchange Commission (SEC) involving whether employees at the US Centers for Medicare & Medicaid Services (CMS) tipped off stock traders ahead of news involving whether the agency would cover the $93,000 cost of the drug.